Despite what you may have heard about drug pricing and expenses getting out of hand, net spending growth actually fell in the U.S. last year. After discounts, pharmaceutical spending increased 4.8% in 2016, down from 8.9% growth recorded in 2015.
The figures are courtesy of the QuintilesIMS Institute, which released its annual drug spending report on Thursday. All told, net U.S. drug expenses reached $323 billion last year, while invoice-level spending was $450 billion.
Taken together, the figures represent an industrywide rebate and discounting level of 28%. Spending growth also slowed on an invoice basis in 2016, to 5.8%, from about 12.5% in 2015 and about 15% in 2014.
Importantly, the numbers represent overall growth, and drug spending in the U.S. continued to expand in 2016. Last year’s net spending increase followed an 8.9% jump in 2015, and an even higher leap of about 10% for 2014.
Other big industry trends, according to QuintilesIMS, include a continued shift to specialty medicine spending, a deceleration of invoice price hikes, and a downturn in new drug sales. On specialty meds, the experts noted that the class now accounts for $384 of the $895 per person per year spent on pharmaceuticals in the U.S.
For invoice price hikes in recent history, QuintilesIMS’ report notes a high point back in 2014, when average invoice price increases were 13.7% for the year. That number fell to 12% in 2015 and 9.2% last year as the industry continued to grapple with broad pricing pressures. Average price increases after discounts were even lower at 4.5% for 2014, 2.5% for 2015 and 3.5% for last year.
New drugs—those on the market for less than 24 months—generated $13.9 billion in sales last year, a downturn from $17.3 billion in 2015 and $20.6 billion in 2014. As the analysts note, the FDA approved fewer than half the number of new meds last year as it did in 2014 and 2015.
So far this year, however, that trend seems to be reversing. The FDA approved more new meds during the first quarter of 2017 than during the same period of any year in recent history. The agency didn’t stop there, and has since brought its total new drug approval tally to 19 for this year.
Looking ahead, QuintilesIMS experts aren’t expecting huge price increases in the coming years. Report authors write that “drug manufacturer responses to heightened market competition and scrutiny of drug pricing are expected to result in more modest levels of invoice (and net) price growth in the forecast period.”
QuintilesIMS releases its industry analysis as politicians in Washington work to take on drug costs through a variety of proposals, including drug importation and Medicare price negotiation. Their efforts are boosted by broad public support, with a Kaiser Family Foundation poll this week finding that 60% of Americans consider the issue a “top priority” for President Donald Trump and Congress.
By Eric Sagonowsky
Source: Fierce Pharma
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.